Dr. Julie Graff, MD
Claim this profileVA Portland Health Care System, Portland, OR
Studies Prostate Cancer
Studies Cancer
5 reported clinical trials
9 drugs studied
Area of expertise
1Prostate Cancer
Stage IV
RAD51 positive
RAD51C positive
2Cancer
Stage IV
Affiliated Hospitals
Clinical Trials Julie Graff, MD is currently running
High Dose Testosterone
for Prostate Cancer
This study will determine whether the presence of DNA repair deficiency in the form of alterations in the genes ATM, CDK12 or CHEK2 predicts for a high likelihood of responding to the use of intermittent high dose testosterone. This therapy may result in responses in tumors which are genetically unstable because of DNA repair deficiency and this is a prospective study to test that hypothesis
Recruiting3 awards Phase 2
Carboplatin vs Olaparib
for Prostate Cancer
This is an unblinded, randomized clinical study comparing the efficacy of DNA damaging chemotherapy using carboplatin, to standard of care therapy for patients who have metastatic castrate resistant prostate cancer. This trial will use olaparib or carboplatin as initial therapy with crossover to the alternate or second-line drug after first progression for patients with tumors containing BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D, or RAD54L inactivating mutations. Participants are randomized (1:1) and receive either carboplatin (AUC 5, IV) every 21 days, first or olaparib taken orally (300 mg), twice daily in 28 day cycles, until intolerance, complete response, or progression by Prostate Cancer Working Group 3 (PCWG3) criteria. Participants then crossover from the first-line therapy to the second-line therapy with the opposite study medication and receive treatment to intolerance or progression (whichever is first). Enrolled participants will be allowed to crossover to second line therapy if they continue to meet initial eligibility criteria, and at least three weeks have elapsed since last administration of either carboplatin or olaparib. Throughout the study, safety and tolerability will be assessed. Progression will be evaluated with bone scan, CT of the abdomen/pelvis, or MRI and PSA as per PCWG3 criteria.
Recruiting1 award Phase 2
More about Julie Graff, MD
Clinical Trial Related3 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Julie Graff, MD has experience with
- Carboplatin
- Olaparib
- High Dose Testosterone
- Standard Of Care
- MGC018
- ARAT
Breakdown of trials Julie Graff, MD has run
Prostate Cancer
RAD51 Gene Mutation
Breast and Ovarian Cancer Syndrome
Squamous Cell Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Julie Graff, MD specialize in?
Julie Graff, MD focuses on Prostate Cancer and Cancer. In particular, much of their work with Prostate Cancer has involved Stage IV patients, or patients who are RAD51 positive.
Is Julie Graff, MD currently recruiting for clinical trials?
Yes, Julie Graff, MD is currently recruiting for 2 clinical trials in Portland Oregon. If you're interested in participating, you should apply.
Are there any treatments that Julie Graff, MD has studied deeply?
Yes, Julie Graff, MD has studied treatments such as Carboplatin, Olaparib, High dose testosterone.
What is the best way to schedule an appointment with Julie Graff, MD?
Apply for one of the trials that Julie Graff, MD is conducting.
What is the office address of Julie Graff, MD?
The office of Julie Graff, MD is located at: VA Portland Health Care System, Portland, OR, Portland, Oregon 97239 United States. This is the address for their practice at the VA Portland Health Care System, Portland, OR.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.